Bone metabolism Product details

Productname sRANKL, Human, high sensitive

Soluble, non-complexed Human sRANKL

Cat-No. BI-20452

Range 0.125 - 2 pmol/l (1 pg/ml = 0.05 pmol/l)

Sensitivity 0.02 pmol/l = 0.4 pg/ml

Incubation time Overnight plus 1.5 hours

Sample volume 100 µl

Sample type

Serum, plasma (EDTA, Heparin), cell culture

Sample preparation

Store samples at -20 °C or below if not assayed on the same day.
Maximum 4 freeze/thaw cycles. Before use, thaw samples at low temperature and mix them thoroughly. Lipemic or hemolyzed samples may give erroneous results.

Reference values

	Median (pmol/l)
females	0.37
males	0.46

Species

Human, porcine

Tests 96 Tests

Method ELISA

Product informations - Kit Instructions (pdf-File 440 kb)
- Cross-reaction all species (pdf-File 71 kb)
- Bone & Cartilage Metabolism (pdf-File 2,480 kb)

Intended use

sRANKL, soluble receptor activator of nuclear factor (NF)-kB ligand (also: Osteoprotegerin ligand, OPGL) a member of the tumor necrosis factor (TNF) family, is the main stimulatory factor for the formation of mature osteoclasts and is essential for their survival. RANKL is produced by osteoblastic lineage cells and activated T lymphocytes. It activates its specific receptor RANK that is located on osteoclasts and dendritic cells. The effects are counteracted by OPG. Human sRANKL corresponds to free and OPG-bound RANKL. sRANKL is one of the key molecular regulation system for bone remodeling. An increase in RANKL expression leads to bone resorption and bone loss.

Indication:

Postmenopausal and senile Osteoporosis
Glucocorticoid-induced Osteoporosis
Diseases with locally increased resorption activity
Therapy control of OPG treatments
Arthritis
Bone Metastases

Keywords product

sRankl human, ELISA, Postmenopausal osteoporosis, Osteoclasts, Senile osteoporosis, Bone remodeling, Bone metastasis, Arthritis, Glucocortoid-induced osteoporosis, Bone marker

Back to overview print view